Rezdiffra (resmetirom) — Topline data
in 2027
Baseline characteristics of patients from the OLE F4c cohort are similar to patients enrolled in the ongoing MAESTRO-NASH OUTCOMES trial which is expected to read out topline data in 2027.Source filing
MDGL biotech catalysts & pipeline
MADRIGAL PHARMACEUTICALS INC · Data as of 2026-10-25
Upcoming catalysts
Rezdiffra (resmetirom) — Clinical data readout
2028
We expect outcomes data from this trial in 2028.Source filing